Scientists probe immune overreaction in severe COVID-19
NCT ID NCT04351711
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined the immune systems of 120 COVID-19 patients who had trouble breathing. Researchers measured many immune markers in the blood to see if an overactive immune response causes lung damage. They also compared these markers to healthy people and looked for patterns that might predict who is at highest risk of dying. The goal was to find new targets for treatments that calm the immune system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help identify which immune signals predict severe COVID-19, pointing toward new treatments that calm the immune system.
What could go wrong
This is an observational study, not a treatment trial. It only measures immune markers, so it cannot directly lead to a cure or therapy on its own.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nimes
Nîmes, France